tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

DE:PHGN Stock Latest News

Pharming price target lowered to $41 from $42 at Oppenheimer
The FlyPharming price target lowered to $41 from $42 at Oppenheimer
10d ago
PHAR
Pharming: Solid Execution, Resilient Revenue, and Joenja Growth Support Buy Rating Ahead of Key Leniolisib Catalysts
PremiumRatings
Pharming: Solid Execution, Resilient Revenue, and Joenja Growth Support Buy Rating Ahead of Key Leniolisib Catalysts
11d ago
PHAR
Is PHGUF a Buy, Before Earnings?
PremiumPre-Earnings
Is PHGUF a Buy, Before Earnings?
13d ago
Morning Movers: Disney dips following fourth quarter earnings
PremiumThe Fly
Morning Movers: Disney dips following fourth quarter earnings
2M ago
DIS
DVN
Pharming to host virtual investor day
PremiumThe Fly
Pharming to host virtual investor day
2M ago
PHAR
Pharming Hit by FDA Setback on Joenja Pediatric Expansion but Adult Approval Unaffected
PremiumCompany AnnouncementsPharming Hit by FDA Setback on Joenja Pediatric Expansion but Adult Approval Unaffected
2M ago
Pharming receives CRL from U.S. FDA for sNDA for Joenja
Premium
The Fly
Pharming receives CRL from U.S. FDA for sNDA for Joenja
2M ago
PHAR
Pharming price target raised to $42 from $41 at Oppenheimer
Premium
The Fly
Pharming price target raised to $42 from $41 at Oppenheimer
5M ago
PHAR
Pharming Group Reports Strong Q3 2025 Growth
PremiumCompany Announcements
Pharming Group Reports Strong Q3 2025 Growth
5M ago
Pharming Group N.V. Reports Strong Q3 2025 Earnings
PremiumCompany Announcements
Pharming Group N.V. Reports Strong Q3 2025 Earnings
5M ago
PHGUF Upcoming Earnings Report: What to Expect?
PremiumPre-Earnings
PHGUF Upcoming Earnings Report: What to Expect?
5M ago
Pharming announces 20% net reduction in non-commercial, non-medical headcount
PremiumThe Fly
Pharming announces 20% net reduction in non-commercial, non-medical headcount
6M ago
PHAR
Pharming Group’s Leniolisib Gains FDA Approval for Pediatric Use, Expanding Market Potential
PremiumRatingsPharming Group’s Leniolisib Gains FDA Approval for Pediatric Use, Expanding Market Potential
6M ago
PHAR
= Pharming Group NV ADS trading resumes
Premium
The Fly
= Pharming Group NV ADS trading resumes
8M ago
PHAR
= Pharming Group NV ADS trading halted, volatility trading pause
Premium
The Fly
= Pharming Group NV ADS trading halted, volatility trading pause
8M ago
PHAR
Pharming price target raised to EUR 2.45 from EUR 2 at RBC Capital
PremiumThe Fly
Pharming price target raised to EUR 2.45 from EUR 2 at RBC Capital
8M ago
PHAR
Pharming Group N.V. Reports Strong Q2 Earnings
PremiumCompany Announcements
Pharming Group N.V. Reports Strong Q2 Earnings
8M ago
Pharming price target raised to $41 from $40 at Oppenheimer
PremiumThe Fly
Pharming price target raised to $41 from $40 at Oppenheimer
8M ago
PHAR
Pharming Group’s Strong Financial Performance and Strategic Developments Justify Buy Rating
PremiumRatings
Pharming Group’s Strong Financial Performance and Strategic Developments Justify Buy Rating
8M ago
PHAR
Pharming Group Reports Strong Revenue Growth in 2025
PremiumCompany AnnouncementsPharming Group Reports Strong Revenue Growth in 2025
8M ago
Pharming Group’s Growth Potential Boosted by Advances in APDS Diagnosis and Treatment
Premium
Ratings
Pharming Group’s Growth Potential Boosted by Advances in APDS Diagnosis and Treatment
9M ago
PHAR
Pharming management to meet with Oppenheimer
Premium
The Fly
Pharming management to meet with Oppenheimer
10M ago
PHAR

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >